Published Paper Details:

Remdesivir, a drug originally designed to be used for Ebola virus, has antiviral activity against SARS-CoV-2 and has been included in the COVID-19 treatment regimens. Remdesivir is an adenosine nucleotide analog prodrug that is Metabolically activated to a nucleoside triphosphate metabolite (GS-443902). The active nucleoside Triphosphate metabolite is incorporated into the SARS-CoV-2 RNA viral chains, preventing its Replication. The lack of reported drug development and characterization studies with remdesivir in public domain has created a void where information on the absorption, distribution, metabolism, Elimination (ADME) properties, pharmacokinetics (PK), or drug-drug interaction (DDI) is limited.By Understanding these properties, clinicians can prevent sub therapeutic and supra-therapeutic levels of Remdesivir and thus avoid further complications in COVID-19 patients. Remdesivir is metabolized by both cytochrome P450 (CYP) and non-CYP enzymes such as carboxylesterase. In this narrative Review, we have evaluated the currently available ADME, PK, and DDI information about remdesivir and have discussed the potential of DDIs between remdesivir and different COVID-19 drug regimens and agents used for comorbidities.